PR91626

FREIBURG, Germany, Sept. 14, 2021 /PRNewswire=KYODO JBN/--

Eleva, a manufacturer of superior biologics, is scaling up its production

capacity to 2500 l in state-of-the-art single-use reactors. This will produce

enough factor H to cover all three clinical phases.

Eleva has ordered four more state-of-the-art, 500 l single-use reactors from

Sartorius Stedim Systems. The scale-up will enable Eleva to enter clinical

development of factor H, a key component of a pathway of the immune system

known as alternative complement pathway.

The complement system enhances (complements) the body's ability to clear

microbes and damaged cells from an organism. Factor H regulates the activation

of that immune response and ensures the body's own cells are protected.

Insufficient regulation of the complement system leads to excessive

inflammation and potential tissue damage.

Factor H is a complex protein that only Eleva's moss-based platform has thus

far been able to yield in highest – human-like – quality. Eleva has been able

to demonstrate a significant reduction in tissue damage and inflammation in

animal models when its recombinant factor H was supplemented.

Ralf Smit, CBO: "Not only can we now produce sufficient amounts of our own drug

candidates for all clinical stages, but we are also in a position to offer

production capacity at industrial scale."

While Eleva will be pursuing the development of its own pipeline products, it

is also open for joint projects with other pharmaceutical companies.

About Eleva

Based in Freiburg, Germany, Eleva develops novel biological therapies with its

pharmaceutical partners. The privately-held company leverages its unique

moss-based production platform to produce supreme biologics like antibodies,

replacement enzymes, or fusion toxins. Eleva has successfully developed drug

candidates into clinical phases.

Press contact

eleva GmbH

Fabienne Zeitter

pr@elevabiologics.com

Phone: +49 761 470 99 0

www.elevabiologics.com

Source: eleva GmbH